- Protecting Food. Protecting People.
- Annual Report: Achievements Building a Healthier Future
- Elevating Education Across the Diagnostic Pathway
News
In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa.
Swipe for more stories
-
Measuring to reduce environmental impact: how bioMérieux is acting across our diagnostic solutions
Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management. -
bioMérieux invests in France with a new facility to produce innovative diagnostics for the European market
Marcy l’Étoile, France – May 29, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces a strategic investment of more than €250 million to build a new manufacturing facility in France (La Balme-les-Grottes, Isère) dedicated to the production of PCR tests from its BIOFIRE® range. The project is expected to create approximately 400 jobs over time. This new facility will help secure the supply of essential diagnostic solutions for the European market while strengthening the resilience of healthcare systems in the face of infectious diseases. -
First-Quarter 2026 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19